Public Market Listing
Live quotes, historical charts, and market capitalization for Tasly Pharmaceutical Group are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(6 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | Traditional Chinese medicine (multi-component)Botanical | Heart FailureChronic Kidney Disease | |
| Phase 3 | Mesenchymal precursor cells (MPCs)Cell therapy | Heart FailureChronic Low Back Pain | |
| Phase 2 | PD-L1 / VEGFMultispecific antibody | Non-Small Cell Lung Cancer | |
| Phase 2 | Multi-target (ginsenoside)Botanical | Heart Failure | |
| Phase 2 | Traditional Chinese medicine (multi-component)Small molecule | Psoriasis | |
| Phase 1/2 | Cardiac cell therapyCell therapy | Heart Failure |
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (2)
December 2026 (2)
What to watch
What to watch
2027 (1)
July 2027 (1)
What to watch
2028 (1)
June 2028 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent